RA Capital Management L.P. Purchases New Shares in Xencor, Inc. (NASDAQ:XNCR)

RA Capital Management L.P. purchased a new stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 575,000 shares of the biopharmaceutical company's stock, valued at approximately $11,563,000. RA Capital Management L.P. owned 0.82% of Xencor as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also bought and sold shares of XNCR. Linden Thomas Advisory Services LLC lifted its stake in shares of Xencor by 1.6% in the 2nd quarter. Linden Thomas Advisory Services LLC now owns 43,643 shares of the biopharmaceutical company's stock worth $826,000 after acquiring an additional 699 shares during the period. Baillie Gifford & Co. boosted its stake in Xencor by 3.3% during the 2nd quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company's stock valued at $445,000 after purchasing an additional 744 shares in the last quarter. Louisiana State Employees Retirement System increased its position in shares of Xencor by 3.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company's stock valued at $587,000 after purchasing an additional 900 shares during the period. Point72 Asia Singapore Pte. Ltd. raised its stake in shares of Xencor by 8.5% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company's stock worth $244,000 after buying an additional 949 shares in the last quarter. Finally, Diversified Trust Co lifted its holdings in shares of Xencor by 7.8% in the second quarter. Diversified Trust Co now owns 14,076 shares of the biopharmaceutical company's stock valued at $266,000 after buying an additional 1,017 shares during the period.

Analysts Set New Price Targets

A number of research analysts recently issued reports on XNCR shares. Royal Bank of Canada lifted their target price on Xencor from $31.00 to $34.00 and gave the stock an "outperform" rating in a report on Thursday, September 26th. Wedbush reissued an "outperform" rating and set a $38.00 target price on shares of Xencor in a research note on Thursday, November 7th. BMO Capital Markets reissued an "outperform" rating and set a $34.00 price objective (up from $32.00) on shares of Xencor in a research note on Friday, November 8th. Piper Sandler raised shares of Xencor from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $20.00 to $30.00 in a research report on Monday. Finally, JPMorgan Chase & Co. upped their price target on shares of Xencor from $27.00 to $28.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Xencor currently has an average rating of "Buy" and a consensus price target of $36.50.

Xencor Stock Down 1.6 %

NASDAQ:XNCR traded down $0.41 during mid-day trading on Thursday, hitting $25.79. 700,851 shares of the company's stock traded hands, compared to its average volume of 609,295. The firm has a 50 day moving average of $22.31 and a two-hundred day moving average of $20.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. Xencor, Inc. has a 12 month low of $15.31 and a 12 month high of $27.24.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $10.70 million during the quarter, compared to analysts' expectations of $14.59 million. During the same period in the prior year, the business earned ($0.40) earnings per share. Xencor's revenue for the quarter was down 81.9% compared to the same quarter last year. Equities analysts expect that Xencor, Inc. will post -3.71 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Alan Bruce Montgomery sold 13,301 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $27.03, for a total value of $359,526.03. Following the completion of the transaction, the director now directly owns 9,140 shares of the company's stock, valued at approximately $247,054.20. This represents a 59.27 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP John R. Desjarlais sold 68,684 shares of the business's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $23.48, for a total value of $1,612,700.32. Following the completion of the sale, the vice president now directly owns 200,104 shares in the company, valued at approximately $4,698,441.92. This represents a 25.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 136,050 shares of company stock worth $3,277,609 over the last 90 days. Corporate insiders own 5.23% of the company's stock.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.